Robert J. Bitterman - 20 Feb 2023 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Role
President & CEO, Director
Signature
Caitlin Kontulis, attorney-in-fact
Issuer symbol
PHIO
Transactions as of
20 Feb 2023
Net transactions value
$0
Form type
4
Filing time
22 Feb 2023, 18:00:10 UTC
Previous filing
15 Dec 2022
Next filing
05 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHIO Common stock, $0.0001 par value Award $0 +11,000 +177% $0.000000 17,211 20 Feb 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying a restricted stock unit, which shares will vest in two equal annual installments commencing on the first anniversary of the grant date.
F2 Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12.